Cerebrolysin

Cerebrolysin group had higher rates of mRS 0-2 at 90 days (68% vs. 44%, p=0.016, NNT=4.2).; Secondary ICH risk was lower with Cerebrolysin (14% vs. 40%, p=0.02, RR 0.37).; Neurological recovery was faster, with lower NIHSS at day 7 (median 3 vs. 6, p=0.01).; Cerebrolysin was an independent predictor of favorable 3-month outcomes (OR 7.5), especially in diabetic patients (interaction OR 9.6).

Cerebrolysin group had a mean increase of 35.6 points on Western Aphasia Battery vs. 20.8 points in placebo (difference 14.8 points, P<0.001).; Cerebrolysin group showed greater reduction in NIHSS scores (difference 2.1 points, P<0.001).; Cerebrolysin group had greater improvements in functional independence (Barthel Index) and a trend toward reduced disability (modified Rankin Scale).; Adverse events did not differ significantly between groups (P=0.105 for number of patients, P=0.134 for events per patient).

Ginkgolide, edaravone, cinepazide maleate, citicoline, cerebrolysin, minocycline, and ginkgo diterpene lactone meglumine reduced mortality versus conventional treatment.; All drug regimens significantly improved neurological function, with citicoline + vinpocetine ranking highest.; Edaravone, ginkgolide, and edaravone dexborneol had the best balance of high treatment effectiveness and low adverse effects.; Edaravone, minocycline, edaravone dexborneol, ginkgo diterpene lactone meglumine, citicoline, and cerebrolysin had higher adverse effect rates than conventional treatment.

Neuroprotection aims to inhibit neuronal death and reduce disability after acute ischemic stroke.; Citicoline, cerebrolysin, and MLC901 are frequently used in neurorehabilitation clinics.; There is ongoing debate about the efficacy and safety of these neuroprotective agents.

PTSD incidence reaches up to 12.5% among primary care patients.; Cognitive impairments in PTSD include attention deficits, reduced processing speed, executive dysfunction, and verbal learning/memory impairments.; These cognitive deficits are persistent and similar to those in neurodegenerative diseases.; Potential mechanisms involve neuroinflammation, oxidative stress, and reduced neurotrophic factors; Cerebrolysin shows promise as a treatment.

Cerebrolysin probably results in little to no difference in all-cause death (RR 0.90, 95% CI 0.61 to 1.32, moderate-quality evidence).; Cerebrolysin probably results in little to no difference in total serious adverse events (RR 1.15, 95% CI 0.81 to 1.65, moderate-quality evidence).; Cerebrolysin may increase non-fatal serious adverse events (RR 2.15, 95% CI 1.01 to 4.55, moderate-quality evidence), especially with a 30 mL for 10-day dosing schedule (RR 2.86, 95% CI 1.23 to 6.66).; No trials reported on poor functional outcome (death or dependence) or quality of life.

Cerebrolysin showed a beneficial effect on cognitive function (SMD 0.36, 95% CI 0.13 to 0.58; very low-quality evidence).; Global function improved with Cerebrolysin (RR 2.69, 95% CI 1.82 to 3.98; very low-quality evidence).; No difference in adverse effects was found (RR 0.91, 95% CI 0.29 to 2.85; very low-quality evidence).; No new eligible studies were identified since the 2013 review, and the existing evidence is weak due to high risk of bias and heterogeneity.

What is Cerebrolysin?

**Mechanism of Action** Cerebrolysin (FPF-1070) is a porcine brain-derived peptide preparation composed of low-molecular-weight neuropeptides and amino acids. Its mechanism mimics endogenous neurotrophic factors, including brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and

How does Cerebrolysin work?

Porcine brain-derived peptide preparation with neurotrophic-factor-like activity studied in stroke, TBI, and dementia.

What is the research status of Cerebrolysin?

Cerebrolysin is currently classified as clinical trials, with 629 research references on record. This is for research purposes only and is not medical advice.